Medicine & Life Sciences
Type 2 Diabetes Mellitus
100%
Heart Failure
50%
Cardiovascular Diseases
47%
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
42%
Myocardial Infarction
38%
Placebos
37%
Sodium-Glucose Transport Proteins
29%
Diabetes Mellitus
27%
Heart
25%
Hospitalization
25%
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
22%
Kidney
22%
Atherosclerosis
20%
5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
19%
Safety
18%
Randomized Controlled Trials
18%
Glucose
18%
Acute Coronary Syndrome
17%
Mortality
17%
Sitagliptin Phosphate
16%
Stroke
15%
Coronary Artery Disease
15%
Glucagon-Like Peptide-1 Receptor
15%
Confidence Intervals
14%
Coronary Vessels
14%
Linagliptin
13%
Chronic Renal Insufficiency
13%
Population
13%
Glomerular Filtration Rate
12%
Rosiglitazone
12%
Insulin
12%
Brain Natriuretic Peptide
12%
Therapeutics
11%
Hypoglycemic Agents
11%
Calcium
10%
Natriuretic Peptides
10%
Coronary Disease
10%
Meta-Analysis
10%
empagliflozin
10%
Sodium-Glucose Transporter 2 Inhibitors
10%
Hypoglycemia
9%
Body Mass Index
9%
Kidney Diseases
9%
Percutaneous Coronary Intervention
9%
Biomarkers
9%
Registries
8%
Insulin Glargine
8%
Type 1 Diabetes Mellitus
8%
Blood Pressure
8%
Troponin T
8%